Creditor's could have done better than 4.3 with Bioamber. There shouldn't be a single dime outside 4.3 going to them from all this product sold unless it's all a bluff.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.